Inactive Instrument

Genmab Stock price Nasdaq Copenhagen

Equities

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe 04:36:53 2024-03-19 am EDT 5-day change 1st Jan Change
2,046 DKK +68.12% Intraday chart for Genmab +4.14% +14.24%
Sales 2024 * 19.61B 2.86B Sales 2025 * 23.49B 3.42B Capitalization 133B 19.41B
Net income 2024 * 5.18B 754M Net income 2025 * 6.88B 1B EV / Sales 2024 * 5.29 x
Net cash position 2024 * 29.58B 4.31B Net cash position 2025 * 34.56B 5.03B EV / Sales 2025 * 4.2 x
P/E ratio 2024 *
25.7 x
P/E ratio 2025 *
19.6 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.78%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 63 98-12-31
Director of Finance/CFO 46 06-12-31
Chief Operating Officer 53 20-03-22
Members of the board TitleAgeSince
Chairman 63 16-12-31
Director/Board Member 73 03-10-31
Director/Board Member 63 15-12-31
More insiders
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (80%); - income from research and development (12.1%); - other (7.9%): primarily income from partnership agreement. At the end of 2022, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.
Calendar
More about the company
  1. Stock
  2. Equities
  3. Stock Genmab A/S
  4. Stock Genmab - Nasdaq Copenhagen